Compare Lemonade Inc (LMND) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lemonade Inc vs ResMed Inc. — how do they compare? Lemonade Inc trades at $46.46 (market cap $3.63B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 8.8× Lemonade Inc's market cap, and ResMed Inc. pays a 1.16% dividend while Lemonade Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lemonade Inc for 27 Days and ResMed Inc. for 51 Days on average.
| LMND | RMD | |
|---|---|---|
Market Cap | $3.63B | $31.89B |
Volume | 1,544,794 | 618,314 |
Sector | Financials | Health |
52-Week High | $96.57 | $275.96 |
52-Week Low | $43.91 | $182.82 |
Typical Hold Time | 27 Days | 51 Days |
Enterprise Value | $3.49B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lemonade (LMND) trades at $46.91, showing modest daily gains of 0.17%. The stock faces bearish technical signals despite recent earnings beats, with revenue growth accelerating to 32% year-over-year in Q2 2026. The company demonstrates improving fundamentals with gross profit margin at 47.85% and narrowing losses, targeting EBITDA profitability by late 2026. Recent expansion into Alaska and Kentucky markets supports growth trajectory.
Lemonade presents a growth story with improving margins and AI-driven efficiency, but profitability remains elusive. The 33% upside to consensus price target of $67 offers potential reward, though persistent losses and competitive pressures pose significant risks. Investors must weigh the company's expansion momentum against its negative cash flow from operations and high valuation multiples.
ResMed (RMD) trades at $226.73, up 0.33% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming Q1 2027 earnings report and management's focus on 12%-14% EPS growth driven by demand in sleep therapy.
The outlook for RMD is positive, supported by robust fundamentals and analyst consensus, though risks include competitive pressures and ongoing legal investigations. Upside potential exists with a consensus price target of $242.70, representing a 7% increase from current levels, but investors should monitor execution against growth targets and market share dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
